25 Oct 2013, BioSpectrum Bureau , BioSpectrum
Singapore: The Indian Pharmaceutical Alliance (IPA) that represents the domestic drug manufacturing industry in the country has called upon the US Food and Drug Administration (FDA) to initiate a dialogue to understand the issues surrounding the industry.
The IPA, that has 19 major pharmaceutical companies as its members including multinationals like Ranbaxy, Wockhardt, Sun Pharma and Lupin has approached the FDA to also understand the concerns that the US drug regulator has raised with respect to the industry.
IPA Secretary General Mr DG Shah said in a news statement, "Keeping in view the problems that have been highlighted by US FDA during inspections of Indian facilities, we have written to them. We would jointly conduct workshops and initiate dialogues for capacity building and understanding their concerns to be able to address them."
He added that the US FDA authorities have agreed to the proposal and are planning to take it forward soon.
IPA's move comes ahead of increasing allegations by the FDA against big players like Ranbaxy, Wockhardt, RPG Life Sciences and Strides Arcolab.
As per FDA data, over 20 drug manufacturing factories across India were barred from supplying medicines to the US.